FaceHeart, an AI technology and digital health innovator, enables general public to be aware of their health conditions proactively and effectively via its Contactless Single Camera Video-based Vital Sign Measurement, FaceHeart Vitals™. FaceHeart obtained FDA 510(k) certification (Heart Rate) under the category of Class II SaMD (Software As a Medical Device) on Sep.1, 2023. Thereafter, FaceHeart plans to submit approval applications for the rest of its vital sign measurements. Meanwhile, FaceHeart also plans to apply for the similar clearances from the CE Marking (Conformité Européenne) in EU, HSA (Health Sciences Authority) in Singapore and TFDA (Taiwan Food and Drug Administration) in Taiwan. FaceHeart provides a key solution to the new era of the Digital Health industry, specifically in the areas of telemedicine, telehealth, smart healthcare, remote patient monitoring and mobile health applications. All of them are exciting and innovative markets to be explored in the upcoming decades. FaceHeart is in the leading position to capture and capitalize these market opportunities and potentials.

• Video-based vital sign measurement using remote photoplethysmography (rPPG). FaceHeart leverages AI-driven facial tracking and imaging processing to extract physiological signals within 45 seconds, without requiring wearables or contact devices.